NYSE:TARO - Taro Pharmaceutical Industries Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$88.48 -0.98 (-1.10 %)
(As of 12/12/2018 02:41 AM ET)
Previous Close$89.46
Today's Range$87.57 - $91.15
52-Week Range$86.71 - $121.23
Volume39,520 shs
Average Volume62,364 shs
Market Capitalization$3.99 billion
P/E Ratio14.32
Dividend YieldN/A
Beta0.29
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. The company sells and distributes its products principally to drug industry wholesalers, drug store chains, mass merchandisers, healthcare institutions, and private pharmacies. The company was founded in 1959 and is based in Haifa Bay, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Zrt.

Receive TARO News and Ratings via Email

Sign-up to receive the latest news and ratings for TARO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNYSE:TARO
Previous Symbol
CUSIPN/A
Phone972-4847-5700

Debt

Debt-to-Equity RatioN/A
Current Ratio9.18
Quick Ratio8.43

Price-To-Earnings

Trailing P/E Ratio14.32
Forward P/E Ratio11.57
P/E GrowthN/A

Sales & Book Value

Annual Sales$661.91 million
Price / Sales5.27
Cash Flow$5.8713 per share
Price / Cash Flow15.07
Book Value$56.06 per share
Price / Book1.58

Profitability

EPS (Most Recent Fiscal Year)$6.18
Net Income$211.15 million
Net Margins36.33%
Return on Equity11.99%
Return on Assets10.96%

Miscellaneous

Employees1,490
Outstanding Shares39,430,000
Market Cap$3.99 billion
OptionableOptionable

Taro Pharmaceutical Industries (NYSE:TARO) Frequently Asked Questions

What is Taro Pharmaceutical Industries' stock symbol?

Taro Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TARO."

How often does Taro Pharmaceutical Industries pay dividends? What is the dividend yield for Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries announced a dividend on Monday, November 5th. Investors of record on Tuesday, December 11th will be given a dividend of $12.81 per share on Friday, December 28th. The ex-dividend date is Monday, December 10th. View Taro Pharmaceutical Industries' Dividend History.

How were Taro Pharmaceutical Industries' earnings last quarter?

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) posted its quarterly earnings data on Monday, November, 5th. The company reported $1.60 earnings per share for the quarter, missing the Zacks' consensus estimate of $1.96 by $0.36. The company earned $158.97 million during the quarter, compared to analysts' expectations of $167.40 million. Taro Pharmaceutical Industries had a return on equity of 11.99% and a net margin of 36.33%. View Taro Pharmaceutical Industries' Earnings History.

When is Taro Pharmaceutical Industries' next earnings date?

Taro Pharmaceutical Industries is scheduled to release their next quarterly earnings announcement on Wednesday, February 6th 2019. View Earnings Estimates for Taro Pharmaceutical Industries.

What price target have analysts set for TARO?

1 brokerages have issued 1 year target prices for Taro Pharmaceutical Industries' shares. Their forecasts range from $115.00 to $115.00. On average, they anticipate Taro Pharmaceutical Industries' stock price to reach $115.00 in the next twelve months. This suggests a possible upside of 30.0% from the stock's current price. View Analyst Price Targets for Taro Pharmaceutical Industries.

What is the consensus analysts' recommendation for Taro Pharmaceutical Industries?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Taro Pharmaceutical Industries in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Taro Pharmaceutical Industries.

What are Wall Street analysts saying about Taro Pharmaceutical Industries stock?

Here are some recent quotes from research analysts about Taro Pharmaceutical Industries stock:
  • 1. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We ascribe a price objective of $115 per share, based on a forward EPS multiple of 15.5x applied to our current fiscal 2019 EPS forecast of $7.40 per share." (12/10/2018)
  • 2. According to Zacks Investment Research, "Taro Pharmaceutical Industries is engaged in the production, research and development, and marketing of prescription and over-the-counter pharmaceutical products, with a focus on generic products. In addition to the production of finished dosage form drugs, they also synthesize the pharmaceutical chemicals used in their production. Products are sold through wholesalers, generic drug distributors, drug store chains, mass merchandisers, HMOs, food stores, pharmacies and hospitals. " (10/11/2018)

Has Taro Pharmaceutical Industries been receiving favorable news coverage?

News articles about TARO stock have trended positive on Wednesday, according to InfoTrie. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Taro Pharmaceutical Industries earned a news impact score of 2.6 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 3.0 out of 10, meaning that recent press coverage is unlikely to have an effect on the company's share price in the near future.

Who are some of Taro Pharmaceutical Industries' key competitors?

Who are Taro Pharmaceutical Industries' key executives?

Taro Pharmaceutical Industries' management team includes the folowing people:
  • Mr. Uday V. Baldota, CEO & Director (Age 48)
  • Mr. Mariano Balaguer, CFO, Chief Accounting Officer & VP (Age 45)
  • Mr. Itamar Karsenti, VP & Head of Operations (Age 46)
  • Mr. Itzik Baruch, VP of Technical Services (Age 55)
  • Dr. Roman Kaplan Ph.D., VP of Scientific and Technical Compliance Mang. (Age 71)

Who are Taro Pharmaceutical Industries' major shareholders?

Taro Pharmaceutical Industries' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (1.68%), Renaissance Technologies LLC (0.84%), Acadian Asset Management LLC (0.71%), Dimensional Fund Advisors LP (0.68%), Freestone Capital Holdings LLC (0.36%) and Globeflex Capital L P (0.18%).

Which major investors are selling Taro Pharmaceutical Industries stock?

TARO stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Man Group plc, Morgan Stanley, Freestone Capital Holdings LLC, Credit Suisse AG, JPMorgan Chase & Co., JPMorgan Chase & Co. and ARK Investment Management LLC.

Which major investors are buying Taro Pharmaceutical Industries stock?

TARO stock was purchased by a variety of institutional investors in the last quarter, including Globeflex Capital L P, Acadian Asset Management LLC, Citadel Advisors LLC, Renaissance Technologies LLC, Jupiter Asset Management Ltd., Alps Advisors Inc., Bank of New York Mellon Corp and American Century Companies Inc..

How do I buy shares of Taro Pharmaceutical Industries?

Shares of TARO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Taro Pharmaceutical Industries' stock price today?

One share of TARO stock can currently be purchased for approximately $88.48.

How big of a company is Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries has a market capitalization of $3.99 billion and generates $661.91 million in revenue each year. The company earns $211.15 million in net income (profit) each year or $6.18 on an earnings per share basis. Taro Pharmaceutical Industries employs 1,490 workers across the globe.

What is Taro Pharmaceutical Industries' official website?

The official website for Taro Pharmaceutical Industries is http://www.taro.com.

How can I contact Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries' mailing address is 14 HAKTOR ST PO BOX 10347, HAIFA BAY L3, 10532. The company can be reached via phone at 972-4847-5700 or via email at [email protected]


MarketBeat Community Rating for Taro Pharmaceutical Industries (NYSE TARO)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  206 (Vote Outperform)
Underperform Votes:  163 (Vote Underperform)
Total Votes:  369
MarketBeat's community ratings are surveys of what our community members think about Taro Pharmaceutical Industries and other stocks. Vote "Outperform" if you believe TARO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TARO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2018 by MarketBeat.com Staff

Featured Article: Day Trading

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel